Table 3 Adjusted mean peak and trough FEV1 and FVC responses at 3 weeks
Difference from placebo, L | ||||||
|---|---|---|---|---|---|---|
End point | Treatment, μg | n | Mean FEV1/FVC response, L (SE) | Mean (SE) | 95 % CI | p value |
FEV1 peak response | Placebo | 201 | 0.227 (0.021) | |||
Olodaterol 2.5 BID | 99 | 0.410 (0.027) | 0.183 (0.023) | 0.138, 0.228 | <0.0001 | |
Olodaterol 5 QD | 99 | 0.380 (0.027) | 0.153 (0.023) | 0.108, 0.198 | <0.0001 | |
Olodaterol 5 BID | 100 | 0.449 (0.027) | 0.222 (0.023) | 0.177, 0.267 | <0.0001 | |
Olodaterol 10 QD | 101 | 0.437 (0.026) | 0.210 (0.023) | 0.165, 0.255 | <0.0001 | |
FEV1 trough response | Placebo | 201 | 0.033 (0.022) | |||
Olodaterol 2.5 BID | 99 | 0.189 (0.027) | 0.156 (0.024) | 0.109, 0.203 | <0.0001 | |
Olodaterol 5 QD | 99 | 0.134 (0.027) | 0.101 (0.024) | 0.054, 0.148 | <0.0001 | |
Olodaterol 5 BID | 100 | 0.229 (0.027) | 0.196 (0.024) | 0.149, 0.243 | <0.0001 | |
Olodaterol 10 QD | 101 | 0.205 (0.027) | 0.172 (0.024) | 0.125, 0.219 | <0.0001 | |
FVC peak response | Placebo | 201 | 0.246 (0.024) | |||
Olodaterol 2.5 BID | 99 | 0.382 (0.030) | 0.136 (0.026) | 0.084, 0.187 | <0.0001 | |
Olodaterol 5 QD | 99 | 0.371 (0.030) | 0.124 (0.026) | 0.073, 0.176 | <0.0001 | |
Olodaterol 5 BID | 100 | 0.390 (0.030) | 0.144 (0.026) | 0.093, 0.195 | <0.0001 | |
Olodaterol 10 QD | 101 | 0.373 (0.029) | 0.126 (0.026) | 0.075, 0.177 | <0.0001 | |
FVC trough response | Placebo | 201 | -0.013 (0.024) | |||
Olodaterol 2.5 BID | 99 | 0.096 (0.031) | 0.110 (0.028) | 0.055, 0.165 | 0.0001 | |
Olodaterol 5 QD | 99 | 0.079 (0.031) | 0.092 (0.028) | 0.037, 0.147 | 0.0010 | |
Olodaterol 5 BID | 100 | 0.105 (0.031) | 0.118 (0.028) | 0.063, 0.172 | <0.0001 | |
Olodaterol 10 QD | 101 | 0.098 (0.031) | 0.111 (0.028) | 0.057, 0.166 | <0.0001 | |